Responses

Download PDFPDF
A 5-year evaluation of the emergency contraception enhanced community pharmacy service provided in Wales
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Regular Contraception user requests declined over the 5 years - another reflection of reduced access to sexual health clinics and GPS?
    • Louise A Massey, Clinical Director Sexual and Reproductive Health Aneurin Bevan University Health Board

    Thank you for the above article. It was noted that over the 5 year period the percentage of consultations for patients who used regular contraception compared with no regular method reduced by a statistically significant amount ( 44.2% to 33.9% p <0.001). A possible explanation for this could be reduced access to clinics and Primary Care in Wales, as England with pressures on all health services. I would welcome any moves in my area of Wales for CPs to provide oral hormonal contraception.

    Conflict of Interest:
    None declared.